Navigation Links
HUYA Bioscience Int'l Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
Date:3/3/2008

Progress validates HUYA's innovative U.S./China pharmaceutical

co-development model

SAN FRANCISCO, March 3 /PRNewswire/ -- IBC Conference -- HUYA Bioscience International (HUYA), the leader in U.S./China pharmaceutical co-development, today announced the completion of three Phase I clinical trial protocols in China of a promising anti-arrhythmic compound, HBI-3000 (Sulcardine sulphate). The data from the trials support a desirable safety profile at dose levels displaying indications of pharmacologic activity. HBI-3000 is being developed as a potential treatment for both atrial and ventricular arrhythmias.

Anti-arrhythmic drugs are used today to treat patients with atrial fibrillation (AF), a serious condition that afflicts 5.6 million Americans. Anti-arrhythmic agents have also been used for the treatment of ventricular arrhythmias, although most have failed to demonstrate a survival advantage, and in some cases carry significant safety risk.

The main concern with anti-arrhythmic drugs is an increased risk of sudden death (Torsade de Pointes) in patients with underlying organic heart disease such as coronary artery disease, prior history of myocardial infarction and heart failure. A large subset of individuals with atrial and ventricular arrhythmias suffers from these conditions, precluding treatment with most existing anti-arrhythmic drugs. Development of safe anti-arrhythmic agents for use in these patients is needed. Pre-clinical data developed by HUYA and its Chinese partner, along with the Chinese clinical trial data suggest that HBI-3000 may have safety advantages over other anti-AF agents and exhibits broad spectrum ion channel inhibition without pro-arrhythmic activity that suggests it may also be safer to use in treatment of ventricular arrhythmias.

According to Mireille Gingras, Ph.D., CEO of HUYA, "the progress on this exciting new compound validates the efficiency and effectiveness of ou
'/>"/>

SOURCE HUYA Bioscience International
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
2. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
5. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
6. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
7. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
8. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
9. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
10. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ... of its lead molecule, Anatabine Citrate, in ... Clinical, The Translational Pharmaceutics Company, based in the ... early development programs. The Company expects to ... of the third quarter with the Medicines Healthcare products ...
(Date:7/31/2014)... 31, 2014 Touro University California,s College of ... as the recipient of a $150,000 grant by the ... University to increase research and classroom space on its ... for the study of health sciences, and will help ... and interests of our students," said Shelley Berkley ...
(Date:7/31/2014)... July 31, 2014 Catylix, Inc. ( ... ( Milpitas, California ) announced today ... and commercialize new fluorination products and related chemistry. ... benefited from the use of substituents that are ... with polarity to improve binding and bioavailability. Fluorinated ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Touro University California Garners Grant From Long Foundation 2Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2
... mental retardation, birth defects, and autism spectrum and ... in New YorkMADISON, N.J., March 17 Quest ... world,s leading provider of diagnostic testing, information and ... genomic hybridization (aCGH) postnatal test is now available ...
... Inc. announced today that it has achieved proof ... Inhibiting Multiple Pathways) kinase platform by designing a ... of both the PI3K (Phosphoinositide-3-kinase) pathway and the ... SF2626 has demonstrated the ability to inhibit both ...
Cached Medicine Technology:Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State 2Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State 3Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State 4Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor 2
(Date:8/1/2014)... Online retailer Disposable Medical Express has ... guarantee on their inventory of Tranquility incontinence care products. ... pads along with other personal care products. , ... a line of incontinence products that you love,” a ... works for you, you shouldn't have to compromise because ...
(Date:8/1/2014)... Stress management can be difficult in this ... concentration and diminish rest and leisure time, stress can mount ... to find a way to manage stress in order to ... “Having a good sense of work-life balance is the key ... founding clinician of SF Custom Chiropractic. “Stress, left unchecked, can ...
(Date:7/31/2014)... Just in time for Washington’s unusually ... is featuring new summertime drink specials on their famed ... locations throughout the season. , A longtime ... customer-nominated Seattle’s best happy hour is well-known for its ... Union location’s 25th anniversary this summer, Duke is now ...
(Date:7/31/2014)... you have asthma, you may have an asthma action plan ... respond to changes and understand when symptoms are getting worse ... you,re doing well, yellow means your asthma has worsened and ... New guidelines are now available to help your allergist steer ... away from the red zone. , "Management of acute loss ...
(Date:7/31/2014)... The 2013 PolyU TSI hit a record ... in 2012. The index measures inbound tourists’ satisfaction ... into an overall index. The 2013 index indicates ... Hong Kong over time. , The index shows ... in Hong Kong are attractions (79.27) and transportation ...
Breaking Medicine News(10 mins):Health News:Disposable Medical Express Offering Low Price Guarantee On Tranquility Products 2Health News:SF Custom Chiropractic Celebrates National Relaxation Day and the Benefits of Massage Therapy for the Month of August 2Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 2Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 3Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3
... -- Could injecting a gene into a patient with ... Physician-scientists are setting out to answer that question in ... severe heart failure. , NewYork-Presbyterian Hospital/Columbia University Medical ... City area where the therapy is currently available. , ...
... will develop training standards and guidelines to ensure ... keeps pace with growth ... To develop first-of-its-kind,guidelines and training standards for ... disease, the Society for,Cardiovascular Angiography and Interventions (SCAI) ...
... Plans to build a second state-of-the-art CCRC across ... MATTHEWS, N.C., June 18 ACTS Retirement-Life,Communities has ... parcel,located near the intersection of Fullwood Lane and ... to add approximately 350 independent,living apartments and single ...
... U.K. study suggests , , WEDNESDAY, June 18 (HealthDay News) ... of anticipating how people might behave during a psychotic ... University of Cambridge, found that patterns of normal brain ... , The researchers compared the brain activity of 15 ...
... in Nation,s 4th Leading Cancer Killer, BETHPAGE, ... Cancer Research, the largest private foundation dedicated,exclusively to ... Request For Proposals (RFP) to identify promising research ... deaths in the United,States., The Lustgarten Foundation,s ...
... the National ... Injury Prevention Program, WASHINGTON, June ... Safety for Seniors Act of 2008,and urges lawmakers to provide ... Center to fully implement this critical,fall prevention initiative., "Millions ...
Cached Medicine News:Health News:First gene therapy for heart failure offered at NewYork-Presbyterian/Columbia 2Health News:SCAI Creates New Council for Rising Interest in Interventional Therapies for Structural Heart Disease 2Health News:SCAI Creates New Council for Rising Interest in Interventional Therapies for Structural Heart Disease 3Health News:ACTS Retirement-Life Communities Signs Land Purchase Agreement on 48-Acre Site in Matthews, North Carolina 2Health News:Brain Activity May Predict Schizophrenia Behavior 2Health News:Lustgarten Foundation Announces 2009 Request for Proposals (RFP) 2Health News:Samarion Praises Congress for Passage of Safety for Seniors Act of 2008 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: